The phase 3 MIRROS trial was a multicenter, randomized, double‐blind, phase 3 study of the MDM2 antagonist idasanutlin plus cytarabine in relapsed/refractory AML. The gene discussed is MDM2; the disease is acute myeloid leukemia.